Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin

Reference

• Sadosky A, McDermott AM, Brandenburg NA, et al. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract Mar 2008;8:45-56
   PubMedGoogle Scholar
• Barrett AM, Lucero MA, Le T, et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med Sep 2007;8 Suppl 2:S50-62
   PubMed Web of Science ®Google Scholar
• Koopman RJ, Mainous AG, 3rd, Liszka HA, et al. Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes. Ann Fam Med 2006;4:427-432
   PubMed Web of Science ®Google Scholar
• Jensen TS, Backonja MM, Hernandez Jimenez S, et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 2006;3:108-119
   PubMedGoogle Scholar
• Horowitz SH. Recent clinical advances in diabetic polyneuropathy. Curr Opin Anaesthesiol 2006;19:573-578
   PubMed Web of Science ®Google Scholar
• Tomlinson D, Young R. Diabetic neuropathies. In: Pickup J, Williams G, eds. Textbook of Diabetes, Vol 2, 3rd Oxford, UK: Blackwell Science, 2003:50.51-51.22
   Google Scholar
• Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population > =40 years of age with and without diabetes: 1999–2000 national health and nutrition examination survey. Diabetes Care 2004;27:1591-1597
   PubMed Web of Science ®Google Scholar
• Rabia K, Khoo EM. Prevalence of peripheral arterial disease in patients with diabetes mellitus in a primary care setting. Med J Malaysia 2007;62:130-133
   PubMedGoogle Scholar
• Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006;81(4 Suppl):S3-11
   PubMed Web of Science ®Google Scholar
• Duby JJ, Campbell RK, Setter SM, et al. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 15 2004;61:160-173; quiz 175-166
   PubMed Web of Science ®Google Scholar
• Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004;21:976-982
   PubMed Web of Science ®Google Scholar
• Bertora P, Valla P, Dezuanni E, et al. Prevalence of subclinical neuropathy in diabetic patients: assessment by study of conduction velocity distribution within motor and sensory nerve fibres. J Neurol 1998;245:81-86
   PubMed Web of Science ®Google Scholar
• Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1997;62:310-318
   PubMed Web of Science ®Google Scholar
• Franklin GM, Shetterly SM, Cohen JA, et al. Risk factors for distal symmetric neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1994;17:1172-1177
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-824
   PubMed Web of Science ®Google Scholar
• Franklin GM, Kahn LB, Baxter J, et al. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 1990;131:633-643
   PubMed Web of Science ®Google Scholar
• Barrett AM, Lucero MA, Le T, et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007;8(Suppl 2):S50-62
   PubMed Web of Science ®Google Scholar
• Sadosky A, McDermott AM, Brandenburg NA, et al. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008;8:45-56
   PubMedGoogle Scholar
• Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006;81(4 Suppl):S12-25
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Otto M, Jensen TS, et al. An evidence-based algorithm for the treatment of neuropathic pain. MedGenMed 2007;9:36
   PubMedGoogle Scholar
• Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-1534
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305
   PubMed Web of Science ®Google Scholar
• Namaka M, Gramlich CR, Ruhlen D, et al. A treatment algorithm for neuropathic pain. Clin Ther 2004;26:951-979
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007;8:503-513
   PubMed Web of Science ®Google Scholar
• Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007;30:437-455
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-1420
   PubMed Web of Science ®Google Scholar
• Raskin J, Wang F, Pritchett YL, et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006;7:373-385
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain 2006;7:399-407
   PubMed Web of Science ®Google Scholar
• Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-356
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-118
   PubMed Web of Science ®Google Scholar
• Stacey BR, Dworkin RH, Murphy K, et al. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med 2008;9:1202-1208
   PubMed Web of Science ®Google Scholar
• Tolle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008;12:203-213
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-263
   PubMed Web of Science ®Google Scholar
• Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253-260
   PubMed Web of Science ®Google Scholar
• Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63:2104-2110
   PubMed Web of Science ®Google Scholar
• Quilici S, Chancellor J, Lothgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009;9:6
   PubMed Web of Science ®Google Scholar
• Tesfaye S. Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care 2009;3:136-143
   PubMedGoogle Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-47
   PubMed Web of Science ®Google Scholar
• LaFleur J, Oderda GM. Methods to measure patient compliance with medication regimens. J Pain Palliat Care Pharmacother 2004;18:81-87
   PubMedGoogle Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
   PubMed Web of Science ®Google Scholar
• Sun P, Wang R, Jacober S. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. Curr Med Res Opin 2007;23:3017-3023
   PubMed Web of Science ®Google Scholar
• Bingenheimer JB, Brennan RT, Earls FJ. Firearm violence exposure and serious violent behavior. Science 2005;308:1323-1326
   PubMed Web of Science ®Google Scholar
• Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004;23:2937-2960
   PubMed Web of Science ®Google Scholar
• Myers J, Louis T. Optimal Propensity Score Stratification. Johns Hopkins University, Dept. of Biostatistics Working Papers 2007(155):1–27. http://www.bepress.com/jhubiostat/paper155
   Google Scholar
• Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-763
   PubMed Web of Science ®Google Scholar
• Rubin DB. On principles for modeling propensity scores in medical research. Pharmacoepidemiol Drug Saf 2004;13:855-857
   PubMed Web of Science ®Google Scholar
• Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 2007;26:20-36
   PubMed Web of Science ®Google Scholar
• Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics 1996;52:249-264
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ye W, Boye KS, et al. Prevalence of other diabetes-associated complications and co-morbidities and its impact on healthcare charges among patients with diabetic neuropathy. J Diabetes Complications 2010;24:9-19
   PubMed Web of Science ®Google Scholar